Biotech Stocks To Add to Your Watchlist - April 24th

Key Points

• MarketBeat's screener names Danaher (DHR), Enveric Biosciences (ENVB), and Vertex Pharmaceuticals (VRTX) as biotech stocks to watch after they recorded the highest dollar trading volume among biotech names in recent days.
• Danaher is a diversified life‑sciences and bioprocess equipment provider offering reagents, single‑use hardware, chromatography and purification technologies that support therapeutic development and manufacturing.
• Enveric is developing psychedelic‑derived small‑molecule treatments (lead candidate EB‑002) for mental‑health disorders, while Vertex is a commercial leader in cystic fibrosis therapies (e.g., TRIKAFTA/KAFTRIO).

Danaher, Enveric Biosciences, and Vertex Pharmaceuticals are the three Biotech stocks to watch today, according to MarketBeat's stock screener tool. Biotech stocks are shares of publicly traded companies that research, develop, and commercialize biological drugs, therapies, diagnostics, and related technologies. For investors they tend to be high-risk, high-reward assets driven by clinical trial results, regulatory approvals, patents and partnerships, and long development timelines, which often leads to elevated volatility and the need for careful due diligence. These companies had the highest dollar trading volume of any Biotech stocks within the last several days.

Danaher (DHR)

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.

Read Our Latest Research Report on DHR

Enveric Biosciences (ENVB)

Enveric Biosciences, Inc., a biotechnology company, engages in the development of small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders. Its lead product candidates are EB-002, an active metabolite of psilocybin, which is in preclinical development stage for the treatment of anxiety disorders; and EB-003 that is in preclinical development stage for the treatment mental health.

Read Our Latest Research Report on ENVB

Vertex Pharmaceuticals (VRTX)

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.

Read Our Latest Research Report on VRTX

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.